Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

By WebmasterJune 28, 2021November 1st, 2024No Comments

Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

Previous PostVenatorx Pharmaceuticals Names Mary Beth Dorr, Ph.D. Vice President, Clinical Science
Next PostRide Health Raises $10 Million to Scale National Medical Transportation Platform